<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26724">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01884415</url>
  </required_header>
  <id_info>
    <org_study_id>HEPATOTRAS</org_study_id>
    <nct_id>NCT01884415</nct_id>
  </id_info>
  <brief_title>Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis</brief_title>
  <official_title>Open-label, Phase III, Randomized, Clinical Trial to Evaluate the Efficacy of Two Different Hepatitis B Virus (HBV) Vaccination Schemes in Patients With Hepatic Cirrhosis Candidates to Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical trial is to compare the response rate obtained with two
      different vaccination schemes against HBV in cirrhotic patients. These patients must be
      candidates for liver transplantation, who have failed seroconversion (anti-HBs &lt; 10 IU/ml)
      after three intramuscular doses of 40 µg.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Post-vaccination serological response</measure>
    <time_frame>At 35 ± 5 days after administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the response rate obtained with two different vaccination schemes against HBV in cirrhotic patients potential candidates for liver transplantation, who have failed seroconversion (anti-HBs &lt; 10 IU/ml) after three intramuscular doses of 40 µg  at 0, 1 and 2 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association of serological response to HBV vaccination to other clinical variables</measure>
    <time_frame>After 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Etiology and severity of cirrhosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of serological response to HBV vaccination to other clinical variables</measure>
    <time_frame>After 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Diabetes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of serological response to HBV vaccination to other clinical variables</measure>
    <time_frame>At baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Body mass index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of serological response to HBV vaccination to other clinical variables</measure>
    <time_frame>At baseline</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Presence of anti-Hepatitis B core antigen positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of serological response to HBV vaccination to other clinical variables</measure>
    <time_frame>After 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Obesity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Cirrhosis</condition>
  <condition>Awaiting Organ Transplant</condition>
  <arm_group>
    <arm_group_label>Second HBV vaccination cycle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Second cycle of HBV vaccination (0, 1 and 2 months)will be administered. Three intramuscular doses of 40 µg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of HBV vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose (40µg) of HBV vaccine will be administered at 6 months after 1 cycle of HBV vaccination</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HBV vaccine</intervention_name>
    <description>Patients receive a second cycle of vaccination</description>
    <arm_group_label>Second HBV vaccination cycle</arm_group_label>
    <other_name>HBVAXPRO 40µg HBV vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HBV vaccine</intervention_name>
    <description>Patients receive vaccination according to the guidelines.</description>
    <arm_group_label>Single dose of HBV vaccine</arm_group_label>
    <other_name>HBVAXPRO 40µg HBV vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Cirrhotic patients, potential candidates for liver transplantation, with indication
             to HBV vaccination (HBsAg negative and anti-HBs negative).

          2. Patients under treatment with HBVAXPRO® who do not show a response after the first
             cycle of vaccination of three intramuscular doses of 40 µg at 0, 1 and 2 months.

          3. Patients over 18 years old.

          4. Negative pregnancy test.

          5. Patients who have given their consent to participate in the study.

        Exclusion Criteria:

          1. Absolute contraindication to HBV vaccine.

          2. Medical history of allergy to any component of the vaccine.

          3. Chronic renal failure on hemodialysis.

          4. Presence of antibodies against Human Immunodeficiency Virus.

          5. Patients with seroconversion (anti-HBs &gt; 10 IU /ml) after the first three doses of
             vaccine.

          6. Lack of consent to participate in the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Manual Pascasio Acevedo, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Virgen del Rocío Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clara M. Rosso Fernández, MD</last_name>
    <phone>0034 955 01 34 14</phone>
    <email>claram.rosso.sspa@juntadeandalucia.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juan Manuel Pascasio Acevedo, MD, PhD</last_name>
    <phone>0034 955 31 22 50</phone>
    <email>jmpascasio@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Virgen del Rocío Hospital</name>
      <address>
        <city>Seville</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clara M. Rosso Fernández, MD</last_name>
      <phone>0034 955 01 34 14</phone>
      <email>claram.rosso.sspa@juntadeandalucia.es</email>
    </contact>
    <contact_backup>
      <last_name>Juan Manuel Pascasio Acevedo, MD, PhD</last_name>
      <phone>0034 955 01 22 50</phone>
      <email>jmpascasio@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Juan Manuel Pascasio Acevedo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Álvaro Giraldez Gallego, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Teresa Ferrer Ríos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raquel Valencia Martín, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José Manuel Sousa Martín, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 13, 2014</lastchanged_date>
  <firstreceived_date>June 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
